Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 10/2017

01-10-2017 | Capsule Commentary

Capsule Commentary on McCoy Et al. Hospital Readmissions Among Commercially-Insured and Medicare Advantage Beneficiaries with Diabetes and the Impact of Severe Hypoglycemic and Hyperglycemic Events

Author: Andrew R. Zullo, PharmD ScM PhD

Published in: Journal of General Internal Medicine | Issue 10/2017

Login to get access

Excerpt

This retrospective cohort study by McCoy et al.1 used administrative data from commercially insured and Medicare Advantage beneficiaries with diabetes to describe the relative frequency of hospital readmissions for severe dysglycemia (hypoglycemia and hyperglycemia) and other causes. It also examined potential predictors of such events. The authors found that the all-cause 30-day readmission rate was 10.8%. Heart failure was the most common cause for readmission (8.9%), and severe dysglycemia accounted for 2.5% of readmissions (38.3% hyperglycemia, 61.0% hypoglycemia, 0.7% unspecified). Younger age, history of dysglycemia, and a higher Diabetes Complications Severity Index score were independent predictors of severe dysglycemia relative to other readmission causes. …
Literature
1.
McCoy RG, Lipska KJ, Herrin J, Moore Jeffery M, Krumholz HM, Shah ND. Hospital readmissions among commercially-insured and medicare advantage beneficiaries with diabetes and the impact of severe hypoglycemic and hyperglycemic events. Journal of General Internal Medicine. 2017; doi:10.​1007/​s11606-017-4095-x.
2.
Edridge CL, Dunkley AJ, Bodicoat DH, Rose TC, Gray LJ, Davies MJ, et al. Prevalence and incidence of hypoglycaemia in 532,542 people with type 2 diabetes on oral therapies and insulin: a systematic review and meta-analysis of population based studies. PloS one. 2015;10(6):e0126427.CrossRefPubMedPubMedCentral
3.
Nunes AP, Yang J, Radican L, Engel SS, Kurtyka K, Tunceli K, et al. Assessing occurrence of hypoglycemia and its severity from electronic health records of patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice. 2016;121:192–203.CrossRefPubMed
4.
Munshi MN, Florez H, Huang ES, Kalyani RR, Mupanomunda M, Pandya N, et al. Management of diabetes in long-term care and skilled nursing facilities: a position statement of the American Diabetes Association. Diabetes Care. 2016;39(2):308–18.CrossRefPubMedPubMedCentral
5.
Zullo AR, Dore DD, Gutman R, Mor V, Smith RJ. National glucose-lowering treatment complexity is greater in nursing home residents than community-dwelling adults. Journal of the American Geriatrics Society. 2016;64(11):e233-e5.CrossRefPubMed
Metadata
Title
Capsule Commentary on McCoy Et al. Hospital Readmissions Among Commercially-Insured and Medicare Advantage Beneficiaries with Diabetes and the Impact of Severe Hypoglycemic and Hyperglycemic Events
Author
Andrew R. Zullo, PharmD ScM PhD
Publication date
01-10-2017
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 10/2017
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-017-4109-8

Other articles of this Issue 10/2017

Journal of General Internal Medicine 10/2017 Go to the issue

Original Research

Substance Use Disorder Treatment Following Clinician-Initiated Discontinuation of Long-Term Opioid Therapy Resulting from an Aberrant Urine Drug Test

Clinical Practice: Clinical Images

Nutritional Deficiency and Acquired Ichthyosis

Clinical Practice: Clinical Images

Coloboma of the Optic Disc and Retina

Capsule Commentary

Capsule Commentary on Klein et al., Categorical Risk Perception Drives Variability in Antibiotic Prescribing in the Emergency Department: a Mixed Methods Observational Study

Original Research

Hospital Readmissions among Commercially Insured and Medicare Advantage Beneficiaries with Diabetes and the Impact of Severe Hypoglycemic and Hyperglycemic Events

Original Research

Randomized Controlled Trial of Brief Mindfulness Training and Hypnotic Suggestion for Acute Pain Relief in the Hospital Setting
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits